Shopping Cart 0
Cart Subtotal
USD 0

Corcept Therapeutics Inc (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept's lead product candidate Korlym (mifepristone) is the first drug candidate to be approved for the treatment of patients with Cushing's syndrome. Other products in the pipeline include mifepristone for psychotic depression; CORT 108297 and other GR antagonists that help in the prevention of antipsychotic-induced weight gain mitigation. Corcept is headquartered in Menlo Park, California, the US.

Corcept Therapeutics Inc (CORT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14

Licensing Agreements 15

Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15

Equity Offering 16

Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16

Corcept Therapeutics Completes Public Offering Of Common Stock For USD 46.4 Million 17

Corcept Therapeutics Completes Private Placement Of Shares For USD 12.4 Million Upon Exercise Of Warrants 18

Asset Transactions 19

Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To USD 45 Million 19

Corcept Therapeutics Inc-Key Competitors 20

Corcept Therapeutics Inc-Key Employees 21

Corcept Therapeutics Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 01, 2018: Corcept Therapeutics announces third quarter 2018 financial results and provides corporate update 23

Aug 09, 2018: Corcept Therapeutics announces second quarter 2018 financial results and stock repurchase program; Provides clinical update 25

May 08, 2018: Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update 28

Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial 29

Feb 01, 2018: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance 31

Nov 02, 2017: Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 32

Aug 01, 2017: Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 33

May 01, 2017: Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 34

Mar 06, 2017: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance 35

Jan 30, 2017: Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results 36

Jan 30, 2017: Corcept Therapeutics Annnounces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Corcept Therapeutics Enters into Agreement with Quotient Clinical 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14

Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15

Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16

Corcept Therapeutics Completes Public Offering Of Common Stock For USD 46.4 Million 17

Corcept Therapeutics Completes Private Placement Of Shares For USD 12.4 Million Upon Exercise Of Warrants 18

Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To USD 45 Million 19

Corcept Therapeutics Inc, Key Competitors 20

Corcept Therapeutics Inc, Key Employees 21

Corcept Therapeutics Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Corcept Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept's lead product candidate Korlym (mifepristone) is the first drug candidate to be approved for the treatment of patients with Cushing's syndrome. Other products in the pipeline include mifepristone for psychotic depression; CORT 108297 and other GR antagonists that help in the prevention of antipsychotic-induced weight gain mitigation. Corcept is headquartered in Menlo Park, California, the US.

Corcept Therapeutics Inc (CORT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14

Licensing Agreements 15

Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15

Equity Offering 16

Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16

Corcept Therapeutics Completes Public Offering Of Common Stock For USD 46.4 Million 17

Corcept Therapeutics Completes Private Placement Of Shares For USD 12.4 Million Upon Exercise Of Warrants 18

Asset Transactions 19

Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To USD 45 Million 19

Corcept Therapeutics Inc-Key Competitors 20

Corcept Therapeutics Inc-Key Employees 21

Corcept Therapeutics Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Nov 01, 2018: Corcept Therapeutics announces third quarter 2018 financial results and provides corporate update 23

Aug 09, 2018: Corcept Therapeutics announces second quarter 2018 financial results and stock repurchase program; Provides clinical update 25

May 08, 2018: Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update 28

Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial 29

Feb 01, 2018: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance 31

Nov 02, 2017: Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 32

Aug 01, 2017: Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 33

May 01, 2017: Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 34

Mar 06, 2017: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance 35

Jan 30, 2017: Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results 36

Jan 30, 2017: Corcept Therapeutics Annnounces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance 37

Appendix 38

Methodology 38

About GlobalData 38

Contact Us 38

Disclaimer 38


List Of Figure

List of Figures

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Corcept Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Corcept Therapeutics Enters into Agreement with Quotient Clinical 11

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13

Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14

Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15

Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16

Corcept Therapeutics Completes Public Offering Of Common Stock For USD 46.4 Million 17

Corcept Therapeutics Completes Private Placement Of Shares For USD 12.4 Million Upon Exercise Of Warrants 18

Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To USD 45 Million 19

Corcept Therapeutics Inc, Key Competitors 20

Corcept Therapeutics Inc, Key Employees 21

Corcept Therapeutics Inc, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Corcept Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.